

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

Hu CD45 BUV805 HI30 100Tst

RRID:AB_2870179

Type: Antibody

Proper Citation

BD Biosciences Cat# 612891, RRID:AB_2870179

Antibody Information

URL: http://antibodyregistry.org/AB_2870179

Proper Citation: BD Biosciences Cat# 612891, RRID:AB_2870179

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD45 BUV805 HI30 100Tst

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2870179

Vendor: BD Biosciences

Catalog Number: 612891

Record Creation Time: 20231110T031927+0000

Record Last Update: 20260829T051210+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD45 BUV805 HI30 100Tst.

No alerts have been found for Hu CD45 BUV805 HI30 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sorrenti E, et al. (2026) Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer. *Cell host & microbe*, 34(3), 425.

Bai Y, et al. (2026) Application of spectral flow cytometry for comprehensive detection of immune metabolism in patient-derived microsamples. *Cell reports methods*, 6(3), 101330.

Braams M, et al. (2026) ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development. *Cell reports. Medicine*, 7(7), 102879.

Sun Z, et al. (2026) Epstein-Barr Virus-Induced Upregulation of GPR183: A Potential Upstream Mechanism in IgG4-Related Ophthalmic Disease. *Investigative ophthalmology & visual science*, 67(8), 30.

Fernandes P, et al. (2026) Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. *Cell host & microbe*, 34(1), 116.

Wright AP, et al. (2026) A high-parameter spectral cytometry protocol for immune subset and functional characterization of cryopreserved human blood with 49 biomarkers. *STAR protocols*, 7(1), 104333.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. *Cancer research communications*, 6(7), 1619.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. *Cell reports*, 44(1), 115156.

Di Meo F, et al. (2025) Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. *Cancer cell*, 43(12), 2298.

Kardava L, et al. (2025) Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection. *Cell reports*, 44(4), 115557.

Pezzella M, et al. (2024) Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. *Journal of hematology & oncology*, 17(1), 127.

Fiore G, et al. (2024) Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy. *Frontiers in immunology*, 15,

1433119.

Trinh T, et al. (2023) CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. *iScience*, 26(4), 106443.

Rosain J, et al. (2023) Human IRF1 governs macrophagic IFN- γ immunity to mycobacteria. *Cell*, 186(3), 621.

Matveev VA, et al. (2023) Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. *iScience*, 26(10), 107915.

Takano T, et al. (2022) Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. *Cell reports. Medicine*, 3(5), 100631.

Rosignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8⁺ T cells predicting outcomes in melanoma patients treated with anti-PD1. *iScience*, 25(6), 104353.

Buckner CM, et al. (2022) Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. *Cell*, 185(23), 4333.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8⁺ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. *Immunity*, 54(6), 1257.

Savage AK, et al. (2021) Multimodal analysis for human ex vivo studies shows extensive molecular changes from delays in blood processing. *iScience*, 24(5), 102404.